机构:[1]Hongqiao International Institute of Medicine, Shanghai Tongren Hospital, and Faculty of Basic Medicine, Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China [2]Department of Biophysics and Kidney Disease Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China 浙江大学医学院附属第一医院[3]Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China [4]Institute of Brain Science, Shuguang Hospital Affiliated with Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China [5]Department of Integrative Biology and Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
This study was supported in part by grants from the National Natural Science
Foundation of China (31830031, 82071510, and 31761163002 to Y.L.), the National
Key Research and Development Program of China (2020YFA0803602 to
Y.L.), and Innovative Research Team of High-Level Local Universities in
Shanghai (SHSMU-ZDCX20211102).
第一作者机构:[1]Hongqiao International Institute of Medicine, Shanghai Tongren Hospital, and Faculty of Basic Medicine, Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Gao Yingwei,Ma Ruining,Weng Weiji,et al.TRPV1 SUMOylation suppresses itch by inhibiting TRPV1 interaction with H1 receptors.[J].CELL REPORTS.2022,39(11):doi:10.1016/j.celrep.2022.110972.
APA:
Gao Yingwei,Ma Ruining,Weng Weiji,Zhang Heng,Wang Yingping...&Li Yong.(2022).TRPV1 SUMOylation suppresses itch by inhibiting TRPV1 interaction with H1 receptors..CELL REPORTS,39,(11)
MLA:
Gao Yingwei,et al."TRPV1 SUMOylation suppresses itch by inhibiting TRPV1 interaction with H1 receptors.".CELL REPORTS 39..11(2022)